FDA Clearance Tracker · P910073
ENDOTAK LEAD SYSTEM
Last checked: Nov 20, 2026Latest source record: Aug 26, 1993 (this decision)Source: openFDAMethods & limitations
Decided
Aug 26, 1993
Approved
Time to decision
616 days
Received Dec 19, 1991. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P910073
- Device name
- ENDOTAK LEAD SYSTEM
- Applicant
- Boston Scientific
- Applicant location
- St Paul, MN
- Received
- Dec 19, 1991
- Decided
- Aug 26, 1993
- Decision
- Approved
- Supplements
- 179 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the 0060 Series ENDOTAK® Lead System. The ENDOTAK® Lead System (hereafter referred to as the ENDOTAK® Lead System) consists of the following: the ENDOTAK® C Lead Models 0060, 0062, 0064; Lead Stylet Models 6824 and 6825; ENDOTAK® SQ Patch Lead Model 0063; commercially available AICD Y Connector Model 6836; and Model 0056 Bipolar Positive Fixation Lead and Adapter. The ENDOTAK® Lead System is used with commercially available AICD Models 15050, 1555, and 1600. The ENDOTAK® Lead System is a transvenous defibrillation leads system and is intended for the treatment of ventricular tacharrhythmias in patients who are at high risk of sudden cardiac death. Such patients are defined as those who have experienced one or more of the following: (1) survived at least one episode of cardiac arrest presumable due to hemodynamically unstable ventricular tachyarrhythmias unassociated with acute myocardial infarction; or (2) recurrent ventricular tachyarrhythmias in the absence of such previous arrest and are inducible into sustained hypotensive ventricular tachycardia (VT) or ventricular fibrillation (VF) despite conventional antiarrhythmic drug therapy.A major consideration in choosing the ENDOTAK® Lead System is that it does not require a thoracotomy. The physician should weigh its advantages against the patients ability to withstand additional electrophysiological (EP) testing (arrhythmia induction and conversion testing), and a possible thoracotomy, should the lead system prove ineffective.Various factors such as cardiomegaly or drug therapy may necessitate repositioning of the defibrillating leads, or substitution of one lead system for another in order to facilitate arrhythmia conversion. In some cases, reliable arrhythmia conversion may not be obtained with any leads at the available AICD energy levels.Bipolar pacmakers may be used with the ENDOTAK® Lead System and AICD pulse generator as long as the pacemaker and AICD pulse generator do not interact causing AICD pulse generator nondetection or false detection.The ENDOTAK® SQ Patch Lead is intended for chronic subcutaneous or submuscular implantation in conjunction with an ENDOTAK® C Lead. The ENDOTAK® SQ Patch Leas is not intended for epicardial or pericardial placement.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LWS. The earliest in FDA's data is P830060, decided Oct 4, 1985.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Boston Scientific
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
- Rezum System510(k)
K262460 · Decided Sep 3, 2026 · 48 days after receipt
Device type: Unit, Electrosurgical, Endoscopic (With Or Without Accessories) (KNS) · GI, Urology & Nephrology
K261153 · Decided Aug 26, 2026 · 140 days after receipt
Device type: Ureteroscope And Accessories, Flexible/Rigid (FGB) · GI, Urology & Nephrology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.